Background: Pneumonia remains the leading infectious cause of death among children. Most cases are less than 2 years old. Around 8,388 Egyptian children died every year due to pneumonia in the past 5 years.
Objectives:Our study aimed at identifying the prevalence of multi drug resistant microbes in CAP versus HAP in paediatric cardiac patients. Patients and Methods:The present cross-sectional study was conducted at Cardiology, Chest and ICU units of PediatricZagazig University Hospital; Faculty of Medicine, Egypt during a period of six months from 1/1/2019 to 30/6/2019. 84 cardiac patients included in our study, classified into two groups: Group A: 73 cardiac patients admitted with bacterial CAP. Group B: 11 cardiac patients developed HAP after admission.
Results: Klebsiella p. was mostly sensitive to Colistin and Amikacin. E. Coli was mostly sensitive to Amikacin, Tobramycin and Tigecycline. Pseudomonas A. was mostly sensitive to Colistin and aminoglycosides. Acinetobacter B. was mostly sensitive to Amikacin, Minocycline, colistin and RD. Streptococcus P. was mostly sensitive to Vancomycin the penicillin and Amikacin. Among the 73 cases of CAP group, 65(89%) improved and 8(11%) died.
Conclusion: Resistance of pathogens of LRTI to different antibiotics has increased with emergence of high percentage of multi-drug resistant strains. Amikacin, Colistin (not used in pediatrics), Tigecycline and Linezolid proved to be the most potent antibiotics against most of CAP and HAP pneumonia, but restriction of their use is important to prevent emergence of resistant strains.
Keywords: Klebsiella pneumonia ,Community Acquired Pneumonia,Hospital Acquired pneumonia